Halozyme Therapeutics (HALO) EBT (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EBT data on file, last reported at $180.3 million in Q1 2026.

• EBT for Q1 2026 came in at $180.3 million, up 25.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $503.4 million (down 16.79% YoY), and the FY2025 annual result was $466.9 million, down 16.2% from the prior year.
• EBT climbed to $180.3 million in Q1 2026 per HALO's latest filing, from -$100.8 million in the prior quarter.
• Over five years, EBT peaked at $219.0 million in Q3 2025 and troughed at -$100.8 million in Q4 2025.
• A 5-year average of $106.0 million and a median of $101.2 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2025: EBT soared 210.41% in 2023, then plunged 156.59% in 2025.
• A 5-year view of EBT shows it stood at $70.8 million in 2022, then soared by 42.92% to $101.2 million in 2023, then jumped by 76.14% to $178.2 million in 2024, then sank by 156.59% to -$100.8 million in 2025, then surged by 278.81% to $180.3 million in 2026.
• Business Quant data shows HALO's EBT at $180.3 million in Q1 2026, -$100.8 million in Q4 2025, and $219.0 million in Q3 2025.